FOXO4-DRI
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
FOXO4-DRI is listed as longevity / senolytic peptide.
- •Senescent cell clearance (research)
Regulatory status: Research peptide — not approved.
Structure & Properties
Compound: FOXO4-DRI; also known as FOXO4-D-Retro-Inverso.
Pharmacologic class: Longevity / Senolytic Peptide.
Known delivery routes: Intravenous, Intraperitoneal (research).
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
D-retro-inverso peptide disrupts FOXO4–p53 interaction in senescent cells — selectively triggers apoptosis in senescent (not healthy) cells.
- •Selective clearance of senescent cells
- •Improved fitness, fur density, renal function in aged mice
Human Research
Evidence grade: Pre-clinical / Observational
Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.
Laboratory Research
Pre-clinical (Baar et al. 2017)
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Research-only. Reported protocols: 3 consecutive daily IV doses, then wash-out of weeks.
Potential interactions and combinations to avoid
- •No human safety data — not for self-experimentation
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •No human safety data
- •Potential off-target apoptosis
- •Theoretical immune activation
Contraindications
- •Pregnancy
- •Active malignancy
- •Pediatric
- •Any current or prior cancer diagnosis (apoptotic and telomerase pathways are tumor-relevant)
- •Impaired hepatic or renal clearance (senescent-cell debris burden)
- •Active wound healing or post-surgical recovery (senescent cells participate in repair)
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 5 mg/kg in mice; no validated human dose
Frequency: Intermittent in trials
Cycling: Intermittent / pulse dosing in animal models.
IV Infusion
Research-only. 3 consecutive daily IV doses, then wash-out.
IV. Clinician-only. No human safety data.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Standalone; not a stack candidate
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
Function
Dosing
Recommended Time of Day
Any consistent time during the short research cycle.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- IV — clinician only — Antecubital vein or central line. Not for home administration.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Intermittent / pulse dosing in animal models.
Timing & Interactions
- ·No human safety data — not for self-experimentation
- ·Standalone; not a stack candidate
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on FOXO4-DRI and sync them to Vial Lab.
Benefits
- ·Selective clearance of senescent cells
- ·Improved fitness, fur density, renal function in aged mice
Risks
- ·No human safety data
- ·Potential off-target apoptosis
- ·Theoretical immune activation
Contraindications
- ·Pregnancy
- ·Active malignancy
- ·Pediatric
- ·Any current or prior cancer diagnosis (apoptotic and telomerase pathways are tumor-relevant)
- ·Impaired hepatic or renal clearance (senescent-cell debris burden)
- ·Active wound healing or post-surgical recovery (senescent cells participate in repair)
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Research peptide — not approved
Veterinary Use (Pets)
No established veterinary protocol for FOXO4-DRI. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.